Major real-world study confirms benefits of DMTs in reducing risk of disability progression
A large “big data” study has confirmed the benefits of long-term exposure to disease-modifying therapies (DMTs) in terms of reducing the risk of disability progression in patients with relapsing-remitting MS (RRMS).